3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Melanoma
17
Carcinoma, Hepatocellular
5
Neoplasms
4
Urinary Bladder Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Liver Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Uveal Melanoma
2
Stomach Neoplasms
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Neoplasm Metastasis
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Basal Cell
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Turcot syndrome
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Skin Neoplasms
1
Interventions
pegaspargase
5
tislelizumab
2
selinexor
2
fludarabine phosphate
2
Whole-Body Irradiation
2
Tacrolimus
2
Radiotherapy
2
Peripheral Blood Stem Cell Transplantation
2
Oxaliplatin
2
Mycophenolic Acid
2
Gemcitabine
2
Etoposide
2
Cyclophosphamide
2
Busulfan
2
Azacitidine
2
Asparaginase
2
sugemalimab
1
relatlimab
1
pembrolizumab
1
gemcitabine-oxaliplatin regimen
1
fludarabine
1
Vorinostat
1
Valganciclovir
1
Transplantation
1
Tomography, X-Ray Computed
1
Thiotepa
1
Therapeutics
1
Sirolimus
1
Positron-Emission Tomography
1
Polymerase Chain Reaction
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Extranodal NK-T-Cell
×
relatlimab
×
1 year
×
Clear all
NCT05255601
2026-02-25
RELATIVITY-069
Bristol-Myers Squibb
Phase 1/2
Completed
5 enrolled